arrow
S

Stefan Schreiber

University Hospital Schleswig-Holstein
H指数:192
被引数:16.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An ulcerative colitis taxonomy defined by individual patient-reported response trajectories

基于个体患者报告反应轨迹的溃疡性结肠炎分类学

2026-11-090
OA
Tracing NAD+ metabolism uncovers adaptive coordination between host and microbiome during colitis

追踪NAD+代谢揭示结肠炎期间宿主与微生物群的适应性协调

2026-07-250
OAAI
Large-scale analysis of temporal gene expression variation in peripheral blood

外周血中基因表达时序变异的大规模分析

2026-05-290
OAAI
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial

克罗恩病皮下注射英夫利昔单抗个性化治疗中的症状反应动力学:来自随机、安慰剂对照III期LIBERTY-CD试验的见解

2026-03-300
OAAI
IL-22 induces Paneth cell metaplasia in the colonic epithelium of ulcerative colitis, promoting wound healing via REG3A

IL-22在溃疡性结肠炎的结肠上皮中诱导潘氏细胞化生,并通过REG3A促进伤口愈合。

2026-03-280
OAAI
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis

先进疗法在中重度克罗恩病成年患者维持治疗中的疗效和安全性比较: 系统文献回顾和网络荟萃分析

2026-01-190
OAAI
First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort study

首次对炎症性肠病家系队列研究中微生物变化的了解

2025-12-310
PRE
Cross-species engraftment biases and metabolic divergence in gnotobiotic mice humanized with ulcerative colitis microbiota

跨物种移植偏倚及在接种溃疡性结肠炎微生物群的悉生小鼠中的代谢差异

2025-11-240
OAAI
Microbial metabolite indole-3-propionic acid drives mitochondrial respiration in CD4+ T cells to confer protection against intestinal inflammation

微生物代谢产物吲哚-3-丙酸驱动CD4+ T细胞线粒体呼吸,以对抗肠道炎症提供保护。

2025-10-210
OA
Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn’s disease: A prospective observational study

溃疡性结肠炎/克罗恩病患者中 vedolizumab 的长期安全性:一项前瞻性观察研究

2025-10-130
PRE
Atg16l1 and Xbp1 cooperatively protect from transcription-associated mutagenesis and small intestinal carcinogenesis

Atg16l1和Xbp1协同保护免受转录相关突变和小肠致癌作用

2025-10-070
OA
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

抗TL1A抗体,afimkibart,在中度至重度活动性溃疡性结肠炎(TUSCANY-2):一项多中心、双盲、维持治疗、多剂量、随机、安慰剂对照的2b期试验

2025-07-210
PRE
Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial

克罗恩病中的肠道急迫感:美利曲珠单抗在随机对照III期试验中的效果

2025-07-140
OAAI